Leap Therapeutics, Inc. (NASDAQ:LPTX) recovered 57.78% of its value since hitting low of $1.35. The recent move of -8.58% drop pushed the stock to close at $2.13 when trading ended on 3/19/2019. At a recent session, the prices were hovering between $2.11 and $2.97. This company shares are 502.35% off its target price of $12.83 and the current market capitalization stands at $37.3M. The recent change has given its price a 5.1% lead over SMA 50 and -79.22% deficit over its 52-week high. The stock witnessed 29.09% gains, -26.8% declines and -68.54% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found LPTX’s volatility during a week at 21.25% and during a month it has been found around 11.93%.

Leap Therapeutics, Inc. (LPTX) Top Holders

Institutional investors currently hold around $5 million or 39.8% in LPTX stock. Look at its top three institutional owners: Fmr Llc owns $2.23 million in Leap Therapeutics, Inc., which represents roughly 5.98% of the company’s market cap and approximately 44.6% of the institutional ownership. Similar statistics are true for the second largest owner, Dafna Capital Management Llc, which owns 170,000 shares of the stock are valued at $396 thousand. The third largest holder is Renaissance Technologies Llc, which currently holds $380 thousand worth of this stock and that ownership represents nearly 1.02% of its market capitalization.

Leap Therapeutics, Inc. 13F Filings

At the end of December reporting period, 10 institutional holders increased their position in Leap Therapeutics, Inc. (NASDAQ:LPTX) by some 172,713 shares, 11 decreased positions by 521,634 and 7 held positions by 1,238,025. That puts total institutional holdings at 1,932,372 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 40,351 shares while 6 institutional investors sold out their entire positions totaling 401,720 shares.

Leap Therapeutics, Inc. (LPTX) Analyst Guide

Several analysts have released their opinion on Leap Therapeutics, Inc. (NASDAQ:LPTX), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation [T1].